132 related articles for article (PubMed ID: 16305489)
1. Kinases as drug discovery targets in hematologic malignancies.
Hannah AL
Curr Mol Med; 2005 Nov; 5(7):625-42. PubMed ID: 16305489
[TBL] [Abstract][Full Text] [Related]
2. [Kinase inhibitors against hematological malignancies].
Tojo A
Nihon Rinsho; 2014 Jun; 72(6):1118-24. PubMed ID: 25016814
[TBL] [Abstract][Full Text] [Related]
3. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
4. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
[TBL] [Abstract][Full Text] [Related]
5. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
6. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
7. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
8. [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Lipka D; Heidel F; Huber C; Fischer T
Pharm Unserer Zeit; 2008; 37(5):394-403. PubMed ID: 18729264
[No Abstract] [Full Text] [Related]
9. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.
Siveen KS; Prabhu KS; Achkar IW; Kuttikrishnan S; Shyam S; Khan AQ; Merhi M; Dermime S; Uddin S
Mol Cancer; 2018 Feb; 17(1):31. PubMed ID: 29455667
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
Rodrigues MS; Reddy MM; Sattler M
Antioxid Redox Signal; 2008 Oct; 10(10):1813-48. PubMed ID: 18593226
[TBL] [Abstract][Full Text] [Related]
11. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
12. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
Wadleigh M; DeAngelo DJ; Griffin JD; Stone RM
Blood; 2005 Jan; 105(1):22-30. PubMed ID: 15358622
[TBL] [Abstract][Full Text] [Related]
13. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Mohi MG; Boulton C; Gu TL; Sternberg DW; Neuberg D; Griffin JD; Gilliland DG; Neel BG
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3130-5. PubMed ID: 14976243
[TBL] [Abstract][Full Text] [Related]
14. [Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
Hochhaus A; Lahaye T; Kreil S; Berger U; Metzgeroth G; Hehlmann R
Onkologie; 2001 Sep; 24 Suppl 5():65-71. PubMed ID: 11600816
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
16. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
17. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
18. Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.
Wei M; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1064-70. PubMed ID: 21867645
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
